1. Home
  2. REPL vs PRCT Comparison

REPL vs PRCT Comparison

Compare REPL & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

SELL

Current Price

$10.82

Market Cap

1.3B

Sector

Health Care

ML Signal

SELL

Logo PROCEPT BioRobotics Corporation

PRCT

PROCEPT BioRobotics Corporation

HOLD

Current Price

$17.56

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REPL
PRCT
Founded
2015
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
REPL
PRCT
Price
$10.82
$17.56
Analyst Decision
Buy
Hold
Analyst Count
8
15
Target Price
$19.50
★ $22.25
AVG Volume (30 Days)
★ 1.8M
1.3M
Earning Date
11-05-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 1.71
EPS
★ N/A
N/A
Revenue
N/A
★ $308,054,000.00
Revenue This Year
N/A
$28.32
Revenue Next Year
$497.81
$20.48
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 37.22
52 Week Low
$1.50
$16.67
52 Week High
$16.33
$38.11

Technical Indicators

Market Signals
Indicator
REPL
PRCT
Relative Strength Index (RSI) 32.47 45.00
Support Level $6.81 $16.84
Resistance Level $11.05 $29.27
Average True Range (ATR) 0.71 0.99
MACD -0.20 0.12
Stochastic Oscillator 1.83 35.14

Price Performance

Historical Comparison
REPL
PRCT

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

About PRCT PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

Share on Social Networks: